Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 5, 2009, Pages 684-690

  Le May, Cédric ^a   Kourimate, Sanae ^a   Langhi, Cédric ^a   Chétiveaux, Maud ^a   Jarry, Anne ^b   Comera, Christine ^c,f   Collet, Xavier ^c   Kuipers, Folkert ^d   Krempf, Michel ^a,b,e   Cariou, Bertrand ^a,b   Costet, Philippe ^a,e  

^a HÔTEL DIEU   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c INSERM   (France)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e Ctr de Rech en Nutrition Humaine   (France)

^f INRA UR66   (France)

Author keywords

CaCo 2; Chylomicron; Intestine; PCSK9; Postprandial

Indexed keywords

APOLIPOPROTEIN B; CHYLOMICRON; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLIVE OIL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; SUBTILISIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; PCSK9 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR RISK; CELL STRAIN CACO 2; CONFOCAL MICROSCOPY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; INTESTINE CELL; LYMPH ANALYSIS; LYMPH VESSEL; MALE; MOUSE; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SMALL INTESTINE; TRIACYLGLYCEROL BLOOD LEVEL; WILD TYPE; ANIMAL; BLOOD; DUODENUM; GOBLET CELL; ILEUM; METABOLISM; MOUSE MUTANT;

ANIMALS; APOLIPOPROTEINS B; CACO-2 CELLS; CHYLOMICRONS; DUODENUM; ENTEROCYTES; GOBLET CELLS; HUMANS; ILEUM; INTESTINE, SMALL; MICE; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; SERINE ENDOPEPTIDASES; TRIGLYCERIDES;

EID: 65549116032     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.181586     Document Type: Article

References (26)

1. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-156.
2. Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007;32:71-77.
3. Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, Hobbs HH. Binding of PCSK9 to EGF-A repeat of LDL receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007;282:18602-18612.
4. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.
5. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37: 161-165.
6. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309-316.
7. Nordestgaard BG, Benn M, Schnoh P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299-308.
8. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA, Horton JD. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A. 2005;102:5374-5379.
9. Mansbach CM, Gorelick F. Development and physiological regulation of intestinal lipid absorption. II. Dietary lipid absorption, complex lipid synthesis, and the intracellular packaging and secretion of chylomicrons. Am J Physiol Gastrointest Liver Physiol. 2007;293:G645-G650.
10. Hayashi H, Fujimoto K, Cardelli JA, Nutting DF, Bergstedt S, Tso P. Fat feeding increases size, but not number, of chylomicrons produced by small intestine. Am J Physiol. 1990;259:G709-G719.
11. Phillips ML, Pullinger C, Kroes I, Kroes J, Hardman DA, Chen G, Curtiss LK, Gutierrez MM, Kane JP, Schumaker VN. A single copy of apolipoprotein B-48 is present on the human chylomicron remnant. J Lipid Res. 1997;38:1170-1177.
12. Lo CM, Nordskog BK, Nauli AM, Zheng S, Vonlehmden SB, Yang Q, Lee D, Swift LL, Davidson NO, Tso P. Why does the gut choose apolipoprotein B48 but not B100 for chylomicron formation? Am J Physiol Gastrointest Liver Physiol. 2008;294:G344-G352.
13. Martins IJ, Hone E, Chi C, Seydel U, Martins RN, Redgrave TG. Relative roles of LDLr and LRP in the metabolism of chylomicron remnants in genetically manipulated mice. J Lipid Res. 2000;41:205-213.
14. [Recommendations for cryopreservation of cells tumor tissues to be used for molecular analyses]. Ann Pathol. 2001;21:184-201.
15. French Bioethic Law No. 2004-800. 2008.
16. Deleted in proof.
17. Fong LG, Bonney E, Kosek JC, Cooper AD. Immunohistochemical localization of low density lipoprotein receptors in adrenal gland, liver, and intestine. J Clin Invest. 1989;84:847- 856.
18. Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, Prat A. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thomb Vasc Biol. 2004;24: 1454-1459.
19. Kourimate S, Le May C, Langhi C, Jarnoux AL, Ouguerram K, Zair Y, Nguyen P, Krempf M, Cariou B, Costet P. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. J Biol Chem. 2008;283:9666-9673.
20. Langhi C, Le May C, Kourimate S, Caron S, Staels B, Krempf M, Costet P, Cariou B. Activation of the farnesoid X receptor represses pcsk9 expression in human hepatocytes. FEBS Lett. 2008;19:949-955.
21. Fanous MY, Phillips AJ, Windsor JA. Mesenteric lymph: the bridge to future management of critical illness. JOP. 2007;8:374 -399.
22. Graham MJ, Lemonidis KM, Whipple CP, Subramaniam A, Monia BP, Crooke ST, Crooke RM. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res. 2007;48:763-767.
23. Greeve J, Altkemper I, Dieterich JH, Greten H, Windler E. Apoli-poprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J Lipid Res. 1993;34:1367-1383.
24. Twisk J, Gillian-Daniel DL, Tebon A, Wang L, Barrett PH, Attie AD. The role of the LDL receptor in apolipoprotein B secretion. J Clin Invest. 2000;105:521-532.
25. Ishibashi S, Perrey S, Chen Z, Osuga J, Shimada M, Ohashi K, Harada K, Yazaki Y, Yamada N. Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. J Biol Chem. 1996;271:22422-22427.
26. Tremblay AJ, Lamarche B, Ruel I, Hogue JC, Bergeron J, Gagne C, Couture P. Lack of evidence for reduced plasma apo B48 catabolism in patients with heterozygous familial hypercholesterolemia carrying the same null LDL receptor gene mutation. Atherosclerosis. 2004;172:367-373.